Phase II multicenter trial of anthracycline rechallenge with pegylated liposomal doxorubicin plus cyclophosphamide for first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines

Journal of Clinical Oncology

Volumn 27, Issue 35, 2009, Pages 5906-5910

  Trudeau, Maureen E ^a   Clemons, Mark J ^a   Provencher, Louise ^a   Panasci, Lawrence ^a   Yelle, Louise ^a   Rayson, Daniel ^a   Latreille, Jean ^a   Vandenberg, Ted ^a   Goel, Rakesh ^a   Zibdawi, Labib ^a   Rahim, Yasmin ^a   Pouliot, Jean Francois ^a  

^a TORONTO EAST GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; MACROGOL DERIVATIVE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; HAND FOOT SYNDROME; HEART FUNCTION; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; CANADA; DISEASE FREE SURVIVAL; DRUG EFFECT; FEMALE; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; MIDDLE AGED; MORTALITY; PHASE 2 CLINICAL TRIAL; TIME; TREATMENT OUTCOME;

ADULT; AGED; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CANADA; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; MIDDLE AGED; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; STROKE VOLUME; TIME FACTORS; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 73349093775     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.22.7504     Document Type: Article

References (19)

1. Early Breast Cancer Trialists' Group: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005
2. A'Hern RP, Smith IE, Ebbs SR: Chemotherapy and survival in advanced breast cancer: The inclusion of doxorubicin in Cooper type regimens. Br J Cancer 67:801-805, 1993
3. Buzdar AU, Legha SS, Hortobagyi GN, et al: Management of breast cancer patients failing adjuvant chemotherapy with Adriamycin-containing regimens. Cancer 47:2798-2802, 1981
4. Henderson IC, Harris JR: Principles in the management of metastatic disease, in Harris JR, Hellman S, Henderson IC, et al (eds): Breast Diseases. Philadelphia, PA, JB Lippincott Company, 1991, p 629
5. Valagussa P, Rossi A, Tancini G, et al: Is there any effective salvage treatment for relapsing operable breast cancer with N+? Proc Am Soc Clin Oncol 4:56, 1985 (abstr C215)
6. Vorobiof DA, Rapoport BL, Chasen MR, et al: First line therapy with paclitaxel (Taxol) and pegylated liposomal doxorubicin (Caelyx) in patients with metastatic breast cancer: A multicentre phase II study. Breast 13:219-226, 2004
7. Alexopoulos A, Karamouzis MV, Stavrinides H, et al: Phase II study of pegylated liposomal doxorubicin (Caelyx) and docetaxel as first-line treatment in metastatic breast cancer. Ann Oncol 15: 891-895, 2004
8. Rivera E, Valero V, Arun B, et al: Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer. J Clin Oncol 21:3249-3254, 2003
9. Chia S, Clemons M, Martin LA, et al: Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: A multicenter phase II trial. J Clin Oncol 24:2773-2778, 2006
10. O'Brien ME, Wigler N, Inbar M, et al: Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 15:440-449, 2004
11. Al-Batran SE, Meerpohl HG, von Minckwitz G, et al: Reduced incidence of severe palmar-plantar erythrodysesthesia and mucositis in a prospective multicenter phase II trial with pegylated liposomal doxorubicin at 40 mg/m2 every 4 weeks in previously treated patients with metastatic breast cancer. Oncology 70:141-146, 2006
12. Overmoyer B, Silverman P, Holder LW, et al: Pegylated liposomal doxorubicin and cyclophosphamide as first-line therapy for patients with metastatic or recurrent breast cancer. Clin Breast Cancer 6:150-157, 2005
13. Chow LW, Yip AY, Lang BH: A phase II trial of vinorelbine and pegylated liposomal doxorubicin in patients with pretreated metastatic breast cancer. Am J Clin Oncol 30:133-138, 2007
14. Martin M, Garcia-Donas J, Casado A, et al: Phase II study of pegylated liposomal doxorubicin plus vinorelbine in breast cancer with previous anthracycline exposure. Clin Breast Cancer 5:353-357, 2004
15. Hayward JL, Carbone PP, Heusen JC, et al: Assessment of response to therapy in advanced breast cancer. Br J Cancer 35:292-298, 1977
16. Drake RD, Lin WM, King M, et al: Oral dexamethasone attenuates Doxil-induced palmar-plantar erythrodysesthesias in patients with recurrent gynecologic malignancies. Gynecol Oncol 94:320-324, 2004
17. Sparano JA: Cytotoxic therapy and other nonhormonal approaches for the treatment of metastatic breast cancer, in Pasqualini JR (ed): Breast Cancer: Prognosis, Treatment and Prevention. New York, NY, Marcel Dekker, 2002, p 430
18. Lorusso D, Di Stefano A, Carone V, et al: Pegylated liposomal doxorubicin-related palmarplantar erythrodysesthesia ('hand-foot' syndrome). Ann Oncol 18:1159-1164, 2007
19. Singal PK, Iliskovic N: Doxorubicin-induced cardiomyopathy. N Engl J Med 339:900-905, 1998